KC

Multi-factor strategy

[KC @KCnonadvisory]

@DominickCampag @ezmoneymonty @JackMan724444 If raising really happens I am biased to bet this is a tactical m and a chess move. Hope for the best!

[KC @KCnonadvisory]

@HowardBlowsNKTR I wouldn’t bet against a doctor on this stock because my AI says the cancer panic around the maintenance data was driven by those who know too little about biotechs, and yes I was one of them - otherwise I would have sized up more at 70s level.

[KC @KCnonadvisory]

@ezmoneymonty @JackMan724444 @A_May_MD @DominickCampag @JRyan_1981 Can…my intuition is that
If it raises, not the happiest ending for those who look for a deal before FDA filing.

[KC @KCnonadvisory]

@HowardBlowsNKTR @A_May_MD @DominickCampag @JRyan_1981 If that happens more unlikely to raise. But why the sell off? Is it a clever act to bet that mgt misguided the sell sides or that mgt deliberately set a range but ultimately failed to land within?
Btw if price goes up, I still think they would not raise IMO.

[KC @KCnonadvisory]

@DominickCampag @JRyan_1981 @A_May_MD They said “partnerships”…obvious? They had to avoid the word BO. The capital market isn’t efficient enough to reflect this “obvious” due to PTSD - retail/generalists (just like some institutions/HF buying AI/spacex for momentum?) dumped for what they believe to be uncertainties.

[KC @KCnonadvisory]

@DominickCampag @JRyan_1981 Think capital raise highly unlikely let’s see. Already failed the investors for once by not taking generalists seriously enough, not the second time I guess. Gap up for them to strike a better deal I think it makes more sense.

[KC @KCnonadvisory]

@GhostCat_ @seedy19tron Usually feeling too much “chatter” among retail (even when you see minimal hype in X and among your friends) takes place when you don���t have a position and this is more likely a syndrome of fomo.

[KC @KCnonadvisory]

@Longi111 If part 2 is out:
1. Below safe range — defies common sense coz it means having misguided sell sides and against trial reporting rules
2. Within range — priced in, open to debate - open to buyout on scientific metrics?
3. Above range — which signals upside + short squeeze?

[KC @KCnonadvisory]

@Taintslapp12283 Heaven for the brave…and maybe also for those with faith and common sense?

[KC @KCnonadvisory]

@RudyResearch End is expedited release of safety data that is within the “safe” range mentioned in slides. The price we see now (or $70 “floor”) probably reflects the least probable scenario that the safety data is worse than “expected” in slides, which is actually contrary to common sense.

[KC @KCnonadvisory]

@BioTechAlchemy @Taintslapp12283 It’s a multidimensional journey towards scientific truth v. reality, and hopefully ultimately guided by common sense.

[KC @KCnonadvisory]

@RNAiAnalyst 1. Late Jun release cleanses CEO's insider status, freeing BP to offer.
2. Following Jun 1 generalist panic, CEO - given his age, options and track record - should / has to sell?
3. Math: Risk $30 downside (floored at $70, pricing in almost worst case BBW) for $50 plus upside?

[KC @KCnonadvisory]

@realDonaldTrump It’s a drama. You know well that China has survived all storms in history and Americans can’t take the same pain. Guess you would get a good deal as an end game.Stocks will normalize and the whole trade war thing, continuing for ages ahead, would not be as severe as most imagine.